Results 151 to 160 of about 344 (172)

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Lancet, The, 2021
Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto   +2 more
exaly  

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

Ca-A Cancer Journal for Clinicians, 2019
Stephanie Lheureux, Marsela Braunstein, Amit M Oza   +2 more
exaly  

Line-commutated converters

2015
openaire   +1 more source

Cancer Disparities by Race/Ethnicity and Socioeconomic Status

Ca-A Cancer Journal for Clinicians, 2004
Gopal K Singh
exaly  

Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma)

Ca-A Cancer Journal for Clinicians, 2016
Markus Raderer, Barbara Kiesewetter
exaly  

Advances in Prostate Cancer Chemotherapy: A New Era Begins

Ca-A Cancer Journal for Clinicians, 2005
Kenneth J Pienta, David C Smith
exaly  

Antibody–drug conjugates come of age in oncology

Nature Reviews Drug Discovery, 2023
exaly  

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Lancet, The, 2018
Matsatoshi Kudo, Kwang-Hyub Han, Fabio Piscaglia   +2 more
exaly  

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Lancet, The, 2017
Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg   +2 more
exaly  

Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier

Nature Reviews Microbiology, 2018
Eric C Martens, Mahesh S Desai
exaly